Market Place
Sourcing Support
Gilead To Present Late-Breaking Data At IDWeek 2024
09 Oct 2024 //
BUSINESSWIRE
Enforcement Report - Week of October 9, 2024
09 Oct 2024 //
FDA
Gilead recalls 1 lot of Veklury due to glass particle in vial
26 Sep 2024 //
FIERCE PHARMA
Gilead Issues Voluntary Nationwide Recall of One Lot of Veklury
23 Sep 2024 //
FDA
NanoViricides Positioned With Clinical, Pre-Clinical Pipeline, Virus-Kill Tech
01 Jul 2024 //
ACCESSWIRE
Data Further Support the Use of Veklury for People Hospitalized With COVID-19
05 Mar 2024 //
BUSINESSWIRE
CHMP Adopts Positive Opinion to Extend the Use of Veklury
19 Sep 2023 //
BUSINESSWIRE
FDA Approves Veklury to Treat COVID-19 inMild to Severe Hepatic Impairment
24 Aug 2023 //
BUSINESSWIRE
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment
14 Jul 2023 //
BUSINESSWIRE
EMA committee recommends approval of Gilead’ Veklury to treat Covid-19
30 May 2023 //
PHARMBIZ
CHMP Adopts Positive Opinion to Extend the Use of Veklury
26 May 2023 //
BUSINESSWIRE
Gilead touts growth for HIV, cancer groups amid Veklury`s fall
03 Feb 2023 //
FIERCE PHARMA
Gilead quashes microcap biotech`s hope of partnering on oral Covid-19 drug
31 Jan 2023 //
ENDPTS
Gilead Sciences: WHO Expands Recommendation for Veklury (Remdesivir)
28 Sep 2022 //
PRESS RELEASE
Study identifies Covid patients with mutations indicating remdesivir resistance
27 Sep 2022 //
ENDPTS
Remdesivir-Resistant Version of COVID-19 Detected in Organ Transplant Recipients
26 Sep 2022 //
NYULANGONE
WHO Recommends Gilead`s (GILD) Veklury for Severe COVID-19
19 Sep 2022 //
NASDAQ
CHMP Adopts Positive Opinion to Extend Indication of Veklury
16 Sep 2022 //
BUSINESSWIRE
Gilead’s Veklury gets WHO recommendation to treat severe Covid-19
16 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
WHO Expands Recommendation for Veklury to Patients With Severe Disease
15 Sep 2022 //
BUSINESSWIRE
Trio of therapies reduces risk of death in patients with severe COVID-19
11 Aug 2022 //
EUROPEAN PHARMACEUTICAL REVIEW
Gilead reports 1% rise in revenue for Q2 2022
03 Aug 2022 //
PHARMACEUTICAL-TECHNOLOGY
CHMP Adopts Positive Opinion on Veklury to Receive Full MAA for COVID-19
22 Jul 2022 //
BUSINESSWIRE
Gilead Sciences Signs New Joint Procurement Agreement with the EC for Veklury
19 Jul 2022 //
BUSINESSWIRE
NRx tanks as peptide fails NIH trial in severe COVID-19 patients
27 May 2022 //
FIERCEBIOTECH
Lilly`s Olumiant gets full FDA nod for COVID patients on oxygen
12 May 2022 //
FIERCEPHARMA
Gilead`s remdesivir fails to show benefit in European trial
05 Apr 2022 //
HEALTH ET
FDA updates Merck`s Covid-19 pill EUA and reaffirms it as last resort
19 Feb 2022 //
ENDPTS
Gilead’s Veklury shows in vitro activity against ten SARS?CoV?2 variants
14 Feb 2022 //
CLINICALTRIALSARENA
Researchers identify a powerful combination of antivirals to treat COVID-19
14 Feb 2022 //
MEDICAL NET
Phase 2/3 Interim Data Evaluating Veklury in Pediatric Patients With COVID-19
11 Feb 2022 //
BUSINESSWIRE
RedHill Biopharma`s Oral Opaganib Reduces Mortality by 70%
07 Feb 2022 //
PRNEWSWIRE
Study reveals hyperimmune i.v. immunoglobulin doesn`t help COVID-19 patients
28 Jan 2022 //
ECONOMIC TIMES
Gilead’s Veklury obtains FDA approval to treat Covid-19 outpatients
25 Jan 2022 //
PHARMACEUTICAL-TECHNOLOGY
FDA expands use of remdesivir to patients with high risk of hospitalization
22 Jan 2022 //
REUTERS
IPC flags safety alert against Covid-19 drug remdesivir
17 Jan 2022 //
PHARMABIZ
Enforcement Report - Week of January 5, 2022
05 Jan 2022 //
FDA
How pharma giants are investing heavily in R&D to develop patient-friendly drugs
04 Jan 2022 //
PRESS RELEASE
Omicron havoc: Doctors recommending Paracetamol to treat majority of Omicron
02 Jan 2022 //
STORYPIVOT
Veklury demonstrates reduced risk of hospitalisation high-risk patients
23 Dec 2021 //
PHARMAFILE
Veklury demonstrates reduced risk of hospitalisation high-risk patients
23 Dec 2021 //
PHARMAFILE
Gilead Announces New England Journal of Medicine Publication of Data Veklury
22 Dec 2021 //
PRESS RELEASE
EC Expands Indication for Veklury (Remdesivir) in COVID-19 Disease Progression
21 Dec 2021 //
BUSINESSWIRE
NRx provides encouraging safety data of Zyesami in Covid-19 trial
15 Dec 2021 //
CLINICALTRIALSARENA
Gilead recalls 2 lots of COVID-19 drug Veklury after finding glass particulates
07 Dec 2021 //
FIERCEPHARMA
Gilead recalls 55,000 vials of remdesivir after complaint about glass particles
04 Dec 2021 //
DAILYMAIL
NRx Pharmaceuticals Identifies Significantly Higher Likelihood
29 Nov 2021 //
GLOBENEWSWIRE
Pharmexcil urges govt to lift restriction on export of its two products
24 Nov 2021 //
PHARMABIZ
CHMP recommends 11 new medicines for authorization, including two COVID-19 MAb
16 Nov 2021 //
RAPS
Mutation Linked to Remdesivir Resistance Found in Covid Patient
14 Nov 2021 //
FORBES
Dr. Reddy’s API team is a 2021 winner
11 Nov 2021 //
PRESS RELEASE
Dr. Reddy’s API team is a 2021 winner in – API Supplier year at Global generics
11 Nov 2021 //
PRESS RELEASE
Gilead sales rise by 13%, buoyed by anti-COVID-19 drug Veklury
02 Nov 2021 //
PMLIVE
Despite strong quarter, some wonder how long Gilead can rely on coronavirus drug
29 Oct 2021 //
BIOPHARMADIVE
Gilead Sciences Announces Veklury® Donations Help Address the Ongoing COVID-19
19 Oct 2021 //
BUSINESSWIRE
Merck seeks FDA nod for COVID antiviral 10 days after data drop
12 Oct 2021 //
REUTERS
